📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
5 articles
AVG GRADE
HIGH
score: 0.70
SENTIMENT
BEARISH
TOTAL VIEWS
12
CAPR Stock Analysis & AI Grade: HIGH
5 articles analyzed · Sentiment: BEARISH · AI-powered equity research
RECENT COVERAGE · 6 ARTICLES
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Who Suffered Losses to a Securities Class Action – Deadline is September 28, 2026
CAPR is subject to a securities class action lawsuit, with Kaplan Fox alerting investors of losses and establishing a September 28, 2026...
Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026
Capricor Therapeutics (CAPR) has experienced significant shareholder losses, prompting legal action notification from law firm Kaplan...
Capricor Therapeutics Stock Tanks 54% Over FDA Panel's Negative Vote On Deramiocel Effectiveness
Capricor Therapeutics (CAPR) experienced a severe single-day collapse following an FDA advisory committee's rejection of clinical...
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
The Lancet publication of HOPE-3 trial data for Capricor Therapeutics' (CAPR) deramiocel represents a significant validation milestone...
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR)
Capricor Therapeutics (CAPR) faces a significant headwind following a downgrade to Sell, driven by FDA efficacy doubts surrounding its...
Capricor Stock Tanks On FDA AdCom Notes - What Investors Should Know (NASDAQ:CAPR)
Capricor (CAPR) experienced a sharp 65% equity decline following negative FDA Advisory Committee feedback on deramiocel's efficacy...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice